Skip to main content
Clinical Trials/CTRI/2020/12/029922
CTRI/2020/12/029922
Not yet recruiting
未知

Preoperative prediction of residual disease in patients with advanced ovarian malignancy using HE4 and CA 125

Dr Rajlaxmi Mundhra0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: C562- Malignant neoplasm of left ovaryHealth Condition 2: C561- Malignant neoplasm of right ovaryHealth Condition 3: C569- Malignant neoplasm of unspecifiedovary
Sponsor
Dr Rajlaxmi Mundhra
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Dr Rajlaxmi Mundhra

Eligibility Criteria

Inclusion Criteria

  • All patients of epithelial ovarian malignancy planned for primary or interval debulking surgery and those who gives consent to participate in the study.

Exclusion Criteria

  • concomitant treatment for multiple types of primary cancer and decreased kidney function (glomerular filtration rate \<60 mL/min/1\.73 m2\) since this significantly impacts the concentration of HE4\.

Outcomes

Primary Outcomes

Not specified

Similar Trials